Psagot Investment House Ltd. raised its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 46.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,800 shares of the medical research company’s stock after buying an additional 6,300 shares during the quarter. Psagot Investment House Ltd.’s holdings in PRA Health Sciences were worth $2,184,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in PRAH. Standard Life Aberdeen plc grew its stake in PRA Health Sciences by 2.4% in the third quarter. Standard Life Aberdeen plc now owns 132,834 shares of the medical research company’s stock valued at $14,637,000 after acquiring an additional 3,131 shares during the period. JPMorgan Chase & Co. raised its holdings in PRA Health Sciences by 56.8% during the third quarter. JPMorgan Chase & Co. now owns 120,190 shares of the medical research company’s stock worth $13,244,000 after acquiring an additional 43,542 shares in the last quarter. LPL Financial LLC raised its holdings in PRA Health Sciences by 34.7% during the third quarter. LPL Financial LLC now owns 5,897 shares of the medical research company’s stock worth $650,000 after acquiring an additional 1,520 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in PRA Health Sciences by 20.6% during the third quarter. Thrivent Financial for Lutherans now owns 13,907 shares of the medical research company’s stock worth $1,532,000 after acquiring an additional 2,373 shares in the last quarter. Finally, New Mexico Educational Retirement Board raised its holdings in PRA Health Sciences by 13.4% during the third quarter. New Mexico Educational Retirement Board now owns 13,500 shares of the medical research company’s stock worth $1,488,000 after acquiring an additional 1,600 shares in the last quarter. 98.14% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently issued reports on PRAH. BidaskClub lowered PRA Health Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday. ValuEngine lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. Wolfe Research started coverage on PRA Health Sciences in a research note on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Robert W. Baird upped their price objective on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $113.22.
Shares of PRA Health Sciences stock traded up $1.53 on Wednesday, hitting $87.25. The stock had a trading volume of 384,815 shares, compared to its average volume of 526,505. PRA Health Sciences Inc has a twelve month low of $80.28 and a twelve month high of $121.98. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $5.62 billion, a price-to-earnings ratio of 22.20, a PEG ratio of 1.18 and a beta of 1.01.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, February 27th. The medical research company reported $1.21 EPS for the quarter, beating the consensus estimate of $1.18 by $0.03. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The company had revenue of $729.65 million for the quarter, compared to the consensus estimate of $750.67 million. As a group, equities research analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current fiscal year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Read More: How to read a candlestick chart
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.